The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients-Reference-Cited by-同舟云学术

The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients

Published:2007-04-01 Issue:4 Volume:92 Page:1249-1255
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Balas Bogdan¹,Baig Muhammad R.¹,Watson Catherine²,Dunning Beth E.³,Ligueros-Saylan Monica⁴,Wang Yibin⁴,He Yan-Ling²,Darland Celia¹,Holst Jens J.⁵,Deacon Carolyn F.⁵,Cusi Kenneth¹,Mari Andrea⁶,Foley James E.⁴,DeFronzo Ralph A.¹

Affiliation:

1. Division of Diabetes (B.B., M.R.B., C.D., K.C., R.A.D.), Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229

2. Novartis Institutes for Biomedical Research (C.W., Y.-L.H.), Cambridge, Massachusetts 02139

3. PharmaWrite, L.L.C. (B.E.D.), Princeton, New Jersey 08540

4. Novartis Pharmaceuticals Corp. (M.L.-S., Y.W., J.E.F.), East Hanover, New Jersey 07054

5. Panum Institute (J.J.H., C.F.D.), University of Copenhagen, DK-2400 Copenhagen, Denmark

6. Institute of Biomedical Engineering (A.M.), National Research Council, 35127 Padova, Italy

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/92/4/1249/9052035/jcem1249.pdf

Reference23 articles.

1. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.;Villhauer;J Med Chem,2003

2. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys;Dardik;Diabetes,2003

3. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.;Ahren;J Clin Endocrinol Metab,2004

4. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.;Ahren;Diabetes Care,2004

5. Glucagon-like peptide-1 7–36: a physiological incretin in man.;Kreymann;Lancet,1987

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin;Diabetes Care;2024-04-23

2. Advances in clinical research on glucagon;Diabetology International;2024-03-23

3. GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function;Cell Reports;2023-11

4. Targeting HMGB1/PI3K/Akt and NF-κB/Nrf-2 signaling pathways by vildagliptin mitigates testosterone-induced benign prostate hyperplasia in rats;Life Sciences;2023-06

5. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature;Frontiers in Molecular Biosciences;2023-05-23